GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
=== Aggregation === Tropoelastin aggregates at physiological temperature due to interactions between hydrophobic domains in a process called coacervation. This process is reversible and thermodynamically controlled and does not require protein cleavage. The coacervate is made insoluble by irreversible crosslinking.
Chitin is the world's second most abundant natural polymer, with collagen being the first. It is a "linear polysaccharide of β-(1-4)-2-acetamido-2-deoxy-D-glucose". Chitin is highly crystalline and is usually composed of chains organized into β sheet. Due to its high crystallinity and chemical structure, it is insoluble in many solvents. It also has low toxicity in the human body and is inert in the intestines. Chitin also has antibacterial properties. Chitin forms crystals that make fibrils that become surrounded by proteins. These fibrils can bundle to form larger fibers that contribute to the hierarchical structure of many biological materials. These fibrils can form randomly oriented networks that provide the mechanical strength of the organic layer in different biological materials. Chitin provides protection and structural support to many living organisms. It makes up the cell walls of fungi and yeast, the shells of mollusks, the exoskeletons of insects and arthropods. In shells and exoskeletons, the chitin fibers contribute to their hierarchical structure. In nature, pure chitin (100% acetylation) does not exist. It instead exists as a copolymer with chitin's deacetylated derivative, chitosan. When the acetylized composition of the copolymer is over 50% acetylated it is chitin. This copolymer of chitin and chitosan is a random or block copolymer.
== Function == Type IV collagen is the major structural component of basement membranes, which contains two or three COL4A1 proteins. Thus, COL4A1 is abundant and found in all types of basement membranes. The NC1 domain of COL4A1 is an important antiangiogenic molecule to control the formation of new capillaries.
Sources: en.wikipedia.org
The Houthis, officially known as Ansar Allah or Ansarullah, are a Zaydi revivalist and Shia Islamist political and paramilitary organization that emerged from Yemen in the 1990s. It is predominantly made up of Zaydis, whose namesake leadership is drawn largely from the al-Houthi family. The Houthis are backed by Iran, and they are widely considered part of the Iranian-led Axis of Resistance. The group has been a central player in Yemen's civil war, drawing widespread international condemnation for its human rights abuses, including targeting civilians and using child soldiers. The movement is designated as a terrorist organization by some countries. Under the leadership of Zaydi religious leader Hussein al-Houthi, the Houthis emerged as an opposition movement to Yemeni president Ali Abdullah Saleh, whom they accused of corruption and being backed by Saudi Arabia and the United States. In 2003, influenced by the Lebanese Shia political and military organization Hezbollah, the Houthis adopted their official slogan against the United States, Israel, and the Jewish people. Al-Houthi resisted Saleh's order for his arrest, and he was killed by the Yemeni military in Saada in 2004. His death sparked the Houthi insurgency. Since then, the movement has been mostly led by his brother Abdul-Malik al-Houthi. The organization played a role in the Yemeni Revolution of 2011 by participating in street protests and coordinating with other Yemeni opposition groups. They joined Yemen's National Dialogue Conference but later rejected the 2011 reconciliation deal.
Biochemically, GcMAF results from sequential deglycosylation of the vitamin D-binding protein (the Gc protein), which is naturally promoted by lymphocytes (B and T cells). The resulting protein may be a macrophage activating factor (MAF). MAFs are lymphokines that control the expression of antigens on the surface of macrophages, and one of their functions is to make macrophages become cytotoxic to tumors.
Paroxetine is a constrained structural analogue of fluoxetine where the linear phenylpropylamine group of fluoxetine has been folded into a piperidine ring (figure 5). The compound has the possibility of four stereoisomers because it contains two chiral centers, but one of them, the (3S,4R)-isomer, is marketed as paroxetine. Research has shown that stereochemical factors affect affinity of the molecule for SERT where substitution into the 2-ortho-position of either aromatic rings decreases affinity for rat SERT by as much as 10–100 times, where the greatest loss occurs in the phenoxy ring. Paroxetine is the most potent SSRI drug available, but it is less selective for SERT than fluvoxamine and sertraline. Paroxetine also has weak NET inhibition which could contribute to its efficacy in depression, especially at higher doses. As demonstrated in table 2, paroxetine also inhibits the NOSs enzyme which could be the reason for its sexual dysfunction adverse effect, especially in men. Paroxetine shows the highest affinity for muscarinic receptors of all the SSRIs which results in weak anticholinergic activity and therefore undesirable adverse effects.
=== Sovereignty === Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be prioritized distribution first within the UK and to the "highest bidder" – the United States, which made an advance payment of US$1.2 billion to secure 300 million vaccine doses for Americans, even before the AstraZeneca-Oxford vaccine or a Sanofi vaccine was proved safe or effective. Concerns exist about whether some countries producing vaccines may impose protectionist controls by export restrictions that would stockpile a COVID‑19 vaccine for their own population. The Chinese government pledged in May 2020, that a successful Chinese vaccine would become a "global, public good", implying enough doses would be manufactured for both national and global distribution. Unlike mRNA vaccines, which have to be stored at subzero temperatures, inactivated vaccines from Sinovac and Sinopharm require ordinary refrigeration and may have more appeal in developing countries. In November 2021, the Chinese government pledged to donate in 2022 a further 600 million vaccine doses to Africa, and supply another 400 million through other routes including production by Chinese companies in Africa.
Sources: en.wikipedia.org
She was active in that role for over ten years. During that time she was also elected into the Association of American Physicians. In 2015 Dr. Huttenlocher was inducted as a Member of the National Academy of Medicine "for her pioneering studies of cell migration and alterations of cell migration in human diseases." In 2017, Huttenlocher was awarded a UW2020 grant to support her project "Engineering leukocytes generated from human iPS cells to treat human disease." At the same time, she was also elected a Fellow of the American Society for Cell Biology. In May 2020, Huttenlocher was named the Anna Ruth Brummett Professor of Pediatrics and Medical Microbiology and Immunology Chair in honor of her "major contributions to the advancement of knowledge." The following year, she was part of a large team of researchers from the University of Wisconsin Carbone Cancer Center recognized with the Society for the Immunotherapy of Cancer’s Team Science Award for "long-standing contribution to the field of cancer immunotherapy over the past 35 years." Huttenlocher's recent research projects include "Cell migration and wound repair" and "Imaging immunometabolism in live animals during host defense." In 2023, Huttenlocher published the book "From Loss to Memory: Behind the Discovery of Synaptic Pruning". It describes the discovery of synaptic pruning and its current relevance to early learning, autism, schizophrenia and Alzheimer's disease.
The Trails of Cold Steel arc follows Rean Schwarzer and Class VII, a specialized group of students attending Thors Military Academy in the Erebonian Empire. The first game, Trails of Cold Steel was released for the PlayStation 3 and PlayStation Vita in Japan in 2013. Trails of Cold Steel II is a direct continuation of the first game and was released for the PlayStation 3 and Vita in 2014. The third and fourth games, Trails of Cold Steel III and IV, follow Rean in his new role as an instructor of a new Class VII at a branch campus of Thors. Cold Steel III was released for the PlayStation 4 (PS4) in Japan in 2017, while Cold Steel IV was released in the following year. A fifth game, Trails into Reverie, was released in 2020 and acts as an epilogue to both the Crossbell and Erebonia arcs and follows Rean, Lloyd, and a masked character known as C. English versions of Cold Steel and Cold Steel II were released by Xseed Games in 2015 and 2016, respectively. NIS America released Cold Steel III in 2019, IV in 2020, and Trails into Reverie in 2023. A box set containing all five games was released in Japan for the PS4 in July 2022.
=== Positions on trans identity, accusations of transphobia and connections to the far-right === On January 22, 2020, after a collage was posted in the city of Montpellier calling for the inclusion of trans women in the feminist movement with the slogan "sisters not cisTERF" (a pun on "cis", i.e. not trans, and "TERF", meaning "transgender-exclusionary radical feminist"), she commented she felt trans activism had become too important in the collage movement and within feminism on Twitter. She stated in particular that being a woman is a question of biology and that the activism of trans women was insulting and reduced women to a set of patriarchal stereotypes such as makeup and clothes. She denied trans women's womanhood, stating: "Throughout time, men have tried to silence women by silencing their revolts. Today, they do it from the inside by infiltrating our struggles". She refuses trans-inclusive language such as "people with vulvas". Her positions have led to her being considered a "TERF" by intersectional feminists. Following these statements, the Instagram account Collages Féminicides Paris distanced itself from her comments: "Discrimination has always been condemned […]. We're talking about the exclusion of a part of women from the struggle; transphobia is not a debate." She became increasingly marginalized in the collage movement, months after leaving its leadership. She was the subject of numerous insults on social networks, so much so that the collective reacted and specified that it repudiates any "killing rhetoric".
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.